Pexelizumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NamePexelizumab
Drug Alias Name培克珠单抗5G1.1-SCh5G1.1-scFVMonoclonal antibody 5G1.1-SCAnti-C5 monoclonal antibody 5G1-1-SC +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsMyocardial Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[17] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProcter & Gamble Company
Active IndicationsN/A
Inactive IndicationsMyocardial Infarction

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG